Study: NCT04292535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo into the intranasal mucosa
Description: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo into the intranasal mucosa
Description: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 60 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 80 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 120 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer